
Roche’s investigational schizophrenia drug bitopertin has failed to help patients with the disorder’s negative symptoms when pitted against placebo. Two …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

